Correction : Clinical Journal of the American Society of Nephrology

Journal Logo

Erratum

Correction

Clinical Journal of the American Society of Nephrology 11(9):p 1721, September 2016. | DOI: 10.2215/CJN.07690716
  • Free

Sarcina C, Tinelli C, Ferrario F, Pani A, De Silvestri A, Scaini P, Del Vecchio L, Alberghini E, Buzzi L, Baragetti I, Pozzi C. Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy. Clin J Am Soc Nephrol 11: , 2016.

Due to author error, Table 2 contains several incorrect values. The corrected values are bolded below:

Table 2. - Multivariate analysis evaluating association between treatment and time-average proteinuria over time
Parameter Coefficient (95% CI) P Value
Model 1
Proteinuria at baseline, g/d
   <2 Reference
   2–2.9 0.73 (0.38–1.08) <0.001
   ≥3 2.02 (1.17–2.88) <0.001
 Treatment
   None Reference
   CS −0.96 (−1.17 to −0.75) <0.001
   CS+A −0.88 (−1.10 to −0.66) <0.001
 Use of RAS blockers 0.16 (0.02–0.30) 0.12
 eGFR at baseline
   ≥60 ml/min per 1.73 m 2 (CKD 1–2) Reference
   30–59.9 ml/min per 1.73 m 2 (CKD 3) 0.14 (0.02–0.26) <0.001
   <30 ml/min per 1.73 m 2 (CKD 4) 0.47 (0.26–0.68) <0.001
 Interaction between TAp at baseline and treatment
   TAp<2 g/d and no treatment Reference
   TAp 2–2.9 g/d and CS −0.37 (−0.76 to 0.01) 0.06
   TAp 2–2.9 g/d and CS+A −0.43 (−0.84 to −0.02) 0.04
   TAp≥3 g/d and no treatment NP
   TAp≥3 g/d and CS −1.44 (−2.32 to −0.57) 0.001
   TAp≥3 g/d and CS+A −0.66 (−1.54 to 0.22) 0.14
Model 2
 eGFR at baseline
   CKD 1–2 Reference
   CKD 3 −0.27 (−0.73 to 0.20) 0.26
   CKD 4 1.29 (0.96–1.62) <0.001
 Treatment
   None Reference
   CS −1.21 (−3.14 to −1.02) <0.001
   CS+A −0.99 (−1.19 to −0.78) <0.001
 Use of RAS blockers 0.11 (−0.03 to 0.25) 0.12
Proteinuria (g/d) at baseline
   <2 g/d Reference
   2–2.9 g/d 0.39 (0.27–0.51) <0.001
   ≥3 g/d 0.92 (0.77–1.07) <0.001
 Interaction between eGFR at baseline and treatment
   CKD 1–2 and no treatment Reference
   CKD 3 and CS 0.57 (0.08–1.06) 0.02
   CKD 3 and CS+A 0.32 (−0.18 to 0.83) 0.21
   CKD 4 and no treatment NP
   CKD 4 and CS −1.17 (−1.58 to −0.77) <0.001
   CKD 4 and CS+A NP
Model 1: model with interaction between proteinuria at baseline and treatment; model 2: model with interaction between eGRF at baseline and treatment. Results are expressed as coefficient with their 95% confidence interval (95% CI); the coefficient represents the mean variation of outcomes for unit difference of quantitative predictors or between levels of categorical or ordinal predictors. CS, corticosteroids; CS+A: corticosteroids plus azathioprine; RAS, renin-angiotensin system; TAp, time-average proteinuria. NP, not possible for collinearity and empty strata.

Published online ahead of print. Publication date available at www.cjasn.org.

Keywords:

Erratum; correction; proteinuria; Corticosteroids; Azathioprine; nephropathy

Copyright © 2016 by the American Society of Nephrology